Diridavumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Diridavumab
Monoclonal antibody
Type?
SourceHuman
Targethemagglutinin
Clinical data
SynonymsCR6261
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6400H9934N1702O1996S48
Molar mass144.2 kg/mol g·mol−1

Diridavumab (CR6261) (INN[1]) is a monoclonal antibody designed for the treatment of influenza A.[2]

This drug was developed by Janssen Pharmaceutical Companies of Johnson & Johnson.

References[edit]

  1. ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Diridavumab, American Medical Association.